Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EYES Second Sight Medical Products (EYES) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Second Sight Medical Products Stock (NASDAQ:EYES) 30 days 90 days 365 days Advanced Chart Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get EYES alerts:Sign Up Key Stats Today's Range N/A50-Day Range$4.11▼$13.0552-Week Range N/AVolume36,800 shsAverage Volume132,982 shsMarket Capitalization$54.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSecond Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.Read More… This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Receive EYES Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter. Email Address EYES Stock News HeadlinesStartups Like Science and Musk's Neuralink Aim to Help Blind People SeeNovember 13, 2024 | msn.comEye drops claiming to change eye color raise alarm among eye specialists on TikTokNovember 12, 2024 | msn.com[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.November 23, 2024 | Crypto Swap Profits (Ad)I Tried PRFM Injections, the Ultimate Undereye Filler AlternativeNovember 9, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Vivani Medical (VANI) with Buy RecommendationNovember 7, 2024 | msn.comDoes Guy Win The Golden Bachelorette? Joan Hinted at Where They Stand NowNovember 6, 2024 | msn.comOprah Winfrey Issues Stark Warning to Those Planning Not to VoteNovember 5, 2024 | msn.comQ3 2024 GeneDx Holdings Corp Earnings CallOctober 31, 2024 | finance.yahoo.comSee More Headlines EYES Stock Analysis - Frequently Asked Questions How were Second Sight Medical Products' earnings last quarter? Second Sight Medical Products, Inc. (NASDAQ:EYES) released its earnings results on Monday, June, 29th. The medical device company reported ($1.71) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by $0.48. When did Second Sight Medical Products' stock split? Shares of Second Sight Medical Products reverse split before market open on Friday, August 19th 2022. The 1-3 reverse split was announced on Friday, August 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. When did Second Sight Medical Products IPO? Second Sight Medical Products (EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO. What other stocks do shareholders of Second Sight Medical Products own? Based on aggregate information from My MarketBeat watchlists, some other companies that Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Canopy Growth (CGC) and Shopify (SHOP). Company Calendar Last Earnings6/29/2020Today11/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical Equipment Sub-IndustryN/A Current SymbolNASDAQ:EYES CUSIPN/A CIK1266806 Webwww.secondsight.com Phone(818) 833-5000Fax818-833-5067Employees15Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,920,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-13.58% Return on Assets-13.02% Debt Debt-to-Equity RatioN/A Current Ratio22.15 Quick Ratio22.15 Sales & Book Value Annual Sales$3.38 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$4.80 per share Price / BookN/AMiscellaneous Outstanding Shares13,135,000Free Float6,935,000Market Cap$54.38 million OptionableOptionable Beta2.55 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:EYES) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Second Sight Medical Products, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Second Sight Medical Products With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
